Compare Norfolk Southern Corporation (NSC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novartis AG — how do they compare? Norfolk Southern Corporation trades at $333.81 (market cap $75.01B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 4× Norfolk Southern Corporation's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NSC | NVS | |
|---|---|---|
Market Cap | $75.01B | $298.18B |
Sector | Technology | Health |
52-Week High | $350.66 | $168.62 |
52-Week Low | $272.35 | $119.31 |
Enterprise Value | $90.55B | $339.50B |
Dividend Yield | 1.62% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.36, down 2.37% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 21.02% net income margin and consistent earnings beats, with Q2 2026 EPS of $3.52 exceeding expectations. Recent news highlights a potential merger with Union Pacific, adding to positive sentiment amid record revenue growth.
Outlook remains favorable due to operational strength and merger prospects, but risks include high valuation (P/E 28.49) and industry headwinds like fuel costs. Analysts are mixed, with a consensus price target of $369.67, suggesting moderate upside potential from current levels.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
